Nyxoah SA opened lower at $0.89, compared with its previous close of $0.90. In the last trading session, the stock traded between $0.89 and $0.90. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Nyxoah SA is now worth
$ 3.68
Resulting in a loss of
$ 96.32 (96.32%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
+$0.00 (+0.00%)
Day High
$0.90
Day Low
$0.89
Day Open
$0.89
Prev Close
$0.90
Volume
1,62,638
1W Return
2.39%
1M Return
-31.97%
3M Return
-43.75%
6M Return
-72.97%
1Y Return
-84.07%
Market Cap ($ Mn)
89
PE Ratio
-
PB Ratio
2.01
PEG Ratio
-
ROE
-139.36%
ROCE
-91.10%
EPS (TTM)
$-0.33
1 Week
2.39%
1 Month
-31.97%
3 Months
-43.75%
6 Months
-72.97%
9 Months
-80.73%
Nyxoah posts €9.2M Q3 revenue, cuts FY26 guidance to €33-35M
Nyxoah reported Q3 net revenue of €9.2 million, up 19% sequentially. U.S. revenue grew 29% sequentially to €6.7 million; international revenue rose 42% YoY. Full-year 2026 revenue guidance adjusted to €33-35 million due to historical ramp patterns. Gross margin improved to 63.1%, driven by higher volume spreading fixed costs. Operating loss narrowed to €21.9 million; cash balance stood at €77.1 million.
7 days agoCantor Fitzgerald lowers Nyxoah price target to $3, keeps Overweight
Cantor Fitzgerald lowered Nyxoah's price target from $6 to $3. Analyst Sarah James maintained an Overweight rating on the stock. The price target reduction represents a 50% cut from the previous level.
16 days agoNyxoah SA Q3FY26 Results: Sales up 19% QoQ, FY26 guidance cut to €33-35M
Preliminary Q3 global net sales reached ~€9.2 million, up 19% QoQ. US net sales grew 29% QoQ to ~€6.7 million, outpacing global growth. Full-year 2026 revenue guidance lowered to €33-35 million from €36-40 million. Cash and financial assets stood at ~€77.0 million as of September 30, 2026.
24 days agoNyxoah reports 74% AHI reduction in 12-month ACCCESS sleep apnea study
Median AHI reduction of 74.3% observed at 12 months in Complete Concentric Collapse patients. Both co-primary endpoints met: AHI responder rate 77.2%, ODI responder rate 87.7%. No device- or procedure-related serious adverse events reported during the study period. PMA supplement submitted to FDA to expand Genio indication to CCC patients in the US.
28 days agoNyxoah appoints Liam Kelly as CEO to lead US expansion
Liam Kelly appointed CEO effective October 1, 2026. Succeeds Olivier Taelman after seven-year tenure. Focus shifts to US market post-FDA approval of Genio. Kelly previously led Teleflex Inc until January 2026.
1mo agoNyxoah appoints Loïc Moreau as interim CFO, reaffirms FY26 guidance
Loïc Moreau named interim CFO effective Oct 2, 2026. John Landry steps down to pursue new opportunity. FY26 net revenue guidance reaffirmed at €36M-€40M. Gross margin expected between 60% and 62%.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Nyxoah SA is now worth
$ 3.68
Resulting in a loss of
$ 96.32 (96.32%)
Note: Past profits do not guarantee future returns.
